New PrIMAVeRa article in BioProcess International

The PrIMAVeRa consortium is proud to announce the publication of a new article in BioProcess International titled Combating Antimicrobial Resistance: Modeling the Untapped Potential of Monoclonal Antibodies.

The article describes the complementary role that monoclonal antibodies (mAbs) can play towards the reduction of antimicrobial resistance (AMR).  While vaccines offer broad, long-term individual and community-level protection against viral and bacterial infections, monoclonal antibodies provide immediate shorter-term protection of persons at risk of infections. They do so through multiple pathways that reduce the burden on our antibiotic reserves, thus reducing the opportunities for bacterial pathogens to develop resistance. 

“Addressing the enormous burden of antimicrobial resistance will require a combination of complementary interventions. Monoclonal antibodies have the potential to play an important role in this effort but realizing that potential will depend on generating robust evidence of their impact on AMR and accelerating their clinical development so they can be made available to patients.” - Mateusz Hasso-Agopsowicz, Expert on Vaccines and Antimicrobial Resistance

One of the biggest challenges in demonstrating the complementary benefits provided by mAbs is a lack of clinical and epidemiological data, resulting in gaps within the platform being developed by PrIMAVeRa to quantify these effects.  Project partners are bridging these gaps with data assembly, mechanistic modelling, economic evaluation, and scenario testing, to help inform policymakers of the untapped potential benefits that mAb implementation would bring to existing and future vaccine schedules in the ongoing battle against AMR.

Read the full article here:  Combating Antimicrobial Resistance: Untapped mAb Potential

This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.  www.imi.europa.eu

This communication reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.